Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC

[In The News]

China NMPA cleared the IND application of BBT-401 submitted on September 25, 2019 The Phase I clinical study in China will be initiated in May 2020 SEONGNAM, South Korea, Dec. 26, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KOSDAQ: 288330), a clinical stage biotech company...

View the full article